Pre-infection UDCA use was not associated with reduced risk for most long COVID outcomes in patients with SLD. Read more: doi.org/10.3350/cmh.2026.028… #LongCOVID #UDCA #SLD #LiverDisease #CMH

Elevated liver MRI-derived cT1 may reflect systemic patho physiological processes associated with extrahepatic cancer risk. Read more: doi.org/10.3350/cmh.2025.137… #cT1 #MRI #LiverDisease #CancerRisk #Biomarker #CMH

DYNAMO model, incorporating LSM status and clinical covariates, enables personalized surveillance in MASLD. Read more: doi.org/10.3350/cmh.2026.027… #MASLD #Vibration_controlled_transient_elastography #LiverFibrosis #LiverStiffness #RiskPrediction #CMH

LATS2 inactivation drives immunosuppressive microenvironment and anti-PD-1 resistance, which can be reversed by YAP inhibition. Read more: doi.org/10.3350/cmh.2025.099… #ICC #LATS2 #PD_L1 #Immunotherapy #CMH

Rifaximin use was not associated with the development of drug-resistant organisms in this cohort of inpatients with cirrhosis. Read more: doi.org/10.3350/cmh.2026.022… #Rifaximin #Cirrhosis #DrugResistantOrganisms #CMH

Co-targeting SOX9 and YAP1 offers a promising and safe broad-spectrum preventive/therapeutic approach for iCCA, potentially overcoming resistance to YAP1 inhibition. Read more: doi.org/10.3350/cmh.2025.117… #CCA #SOX9 #YAP1 #Drug_resistane #CancerBiology #CMH

HKDC1 is a predictive biomarker and supports polyamine-axis modulation to sensitize HCC to lenvatinib plus PD-1 therapy. Read more: doi.org/10.3350/cmh.2025.126… #HCC #HKDC1 #Lenvatinib #ImmuneEscape #CMH

GAFAD replaces lectin-based AFP-L3 with mass spectrometry-quantified AFP-Fuc% for HCC detection. GAFAD outperforms GALAD and ASAP in viral HCC and shows comparable performance in non-viral disease. Read more: doi.org/10.3350/cmh.2025.124… #HCC #Early_diagnosis #GAFAD #CMH

A novel AAV8-tATP7B vector showed promising efficacy and safety in preclinical models of Wilson's disease. Read more: doi.org/10.3350/cmh.2025.130… #WilsonDisease #GeneTherapy #Copper-transporting ATPases #Adeno-associated virus-8 #LiverDisease #CMH

DNMT1 promotes MASLD progression by epigenetically repressing HNF4α/PPARα-dependent metabolic pathways. Read more: doi.org/10.3350/cmh.2025.109… #MASLD #MASH #DNMT1 #Epigenetics #CMH

Congratulations to Dr. Lung Yi Mak, Dr. Terence Kin Wah Lee, Dr. Vincent Wong, and Dr. Takumi Kawaguchi for winning the best CMH editor awards this year! #CMH #BestEditors #EditorialBoardMeeting #KASL

6th Annual International Editorial Board Meeting of CMH. Always a great pleasure to connect with our outstanding editors! We’re continually inspired by the dedication and insights of our international editorial board. We sincerely appreciate the invaluable suggestions that will guide CMH toward continued growth and excellence. #CMH #EditorialBoardMeeting #KASL

Inhibiting GATA2/IL1β could be a therapeutic strategy in KRAS-mutant BTC. Read more: doi.org/10.3350/cmh.2025.127… #BTC #KRAS #IL1β #SyntheticLethality #CMH

Targeting the ASB11–ERLIN1 axis with the clinically approved ZoA offers a promising therapeutic strategy of cholesterol-targeted HCC therapies. Read more: doi.org/10.3350/cmh.2025.115… #HCC #ERLIN1 #CholesterolMetabolism #SREBP2 #CMH

MARC1 p.A165 ab lation reduces HCC aggressiveness by metabolic reprogramming. Read more: doi.org/10.3350/cmh.2025.126… #HCC #MTARC1 #Hypoxia #EMT #CancerGenetics #CMH

This study identified DDX1-R602-ADMA modification as a novel ADMA modification in CCA. Targeting the USP10-PRMT1-DDX1 axis may represent a significant therapeutic approach for CCA. Read more: doi.org/10.3350/cmh.2025.125… #Cholangiocarcinoma #CCA #PRMT1 #DDX1 #Hypoxia #CMH

This study reveals a novel mechanism by which HCC progression is driven through disruption of the TACC3-KAT2A NOTCH4 axis and FOXM1-mediated insulation of TACC3 from DNMT1 silencing. Read more: doi.org/10.3350/cmh.2025.137… #HCC #FOXM1 #TACC3 #DNMT1 #Epigenetics #AlternativeSplicing #Hepatology #CMH

The Natural History and Individualized Prediction of Liver Stiffness–Based Fibrosis Risk in MASLD

Non-invasive cfDNA analysis enables pre-operative prediction of HCC recurrence after liver transplantation. Read more: doi.org/10.3350/cmh.2025.106… #HCC #LiverTransplantation #LiquidBiopsy #cfDNA #PrecisionMedicine #CMH

Dear authors, reviewers, editors, and our valued colleagues, We are delighted to share exciting news with our research community — the 2025 Impact Factor of Clinical and Molecular Hepatology has been officially updated to 21.7.